IP Library Granted Patent US 9,845,461
Granted Patent B2
US 9,845,461 · App. 14/988,340 · Granted Dec 19, 2017

Method for treating oncological diseases

Inventors: Dmitry Dmitrievich Genkin (St. Petersburg, RU); Viktor Veniaminovich Tets (St. Petersburg, RU); Georgy Viktorovich Tets (St. Petersburg, RU)
Assignee: CLS Therapeutics Limited
C12N9/22A61K38/465C12Y301/21003A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,845,461
App. No.
14/988,340
Granted
Dec 19, 2017
Kind
B2
Abstract

A method to treat cancer and other malignant diseases, said method comprising parenterally administering an agent which destroys blood extracellular DNA into the systemic circulation of a cancer patient to slow down cancer growth. The agent is embodied in the form of a DNase enzyme and, more particularly, as a DNase I enzyme. Doses from 50,000-250,000,000 Kunitz units/day are administered for 5-360 days.

Claims (4)

1. A method of treating a cancer by inhibiting growth of a primary tumor and metastasis in a patient in need thereof, wherein said primary tumor and metastasis are accompanied with elevation of blood extracellular DNA level, said method comprising parenterally administering to the patient a DNase enzyme in doses and regiments which provide depolymerization of blood extracellular DNA, wherein the administration of said DNase results in inhibiting growth of the primary tumor and metastasis.

2. The method of claim 1 , wherein the DNase enzyme is administered in doses and regiments which provide blood plasma DNA-hydrolytic activity to exceed 150 Kunitz units per liter of plasma during more than 12 hours within 24 hours.

3. The method according to claim 2 , wherein the DNase enzyme is human recombinant DNase.

4. The method according to claim 1 , wherein the DNase enzyme is human recombinant DNase.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2017
From: GENKIN, DMITRY DMITRIEVICH; TETS, VIKTOR VENIAMINOVICH; TETS, GEORGY VIKTOROVICH
To: CLS THERAPEUTICS LIMITED
Reel/Frame 043062/0606 →
Priority Claims (2)
WO PCT/RU2003/000304 · Jul 14, 2003 · international
RU 2004108057 · Mar 12, 2004 · national
Continuity (5)
Continuation 14203383 · Mar 10, 2014
Continuation 12708914 · Feb 19, 2010
Continuation In Part 11919141
Continuation In Part 10564609
Related Publication 20160130570A1 · May 12, 2016